Maball (rituximab biosimilar) / Hetero - LARVOL DELTA

Consequences of Switching Originator Biological Therapies to Its Biosimilars in Patients with Immune-mediated Diseases in a Mexican Cohort (ACR Convergence 2024) - "Patients who were switched from an originator biological to its biosimilar were followed up every 3 months; biological therapies included were: Adalimumab (ADA), Rituximab (RTX) and Etanercept (ETN), with their biosimilars Amgevita, Maball and Infinitam, respectively. Switching of originator biological therapies to its biosimilar in our cohort of patients might not have an impact on efficacy or the incidence of infections; however, one of the most common AEs was associated with the mechanics of the autoinjector device. Although this may seem a minor issue, it led to patients missing a dose, thus having an impact on treatment compliance and thus the activity of the disease."

Clinical • Ankylosing Spondylitis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Musculoskeletal Pain • Psoriasis • Psoriatic Arthritis • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Systemic Lupus Erythematosus

Identification of therapy-induced senescent targets in non-Hodgkin lymphoma (EACR 2024) - "Introduction Non-Hodgkin lymphoma (NHL) constitutes 90% of all lymphomas, and despite its heterogeneity, the standard treatment remains being R-CHOP, a combination of chemotherapy; cyclophosphamide, doxorubicin and vincristine (CHO); with rituximab. Moreover, we have evaluated different strategies to inhibit these senescence markers and their consequences. With the idea of stratifying patients that could benefit from these novel regimens, we have correlated the expression of certain genes in peripheral blood in response to CHO.Conclusion Integrating transcriptomic data and validation studies, we strive to identify and evaluate senescence targets, potentially offering new therapeutic avenues to disrupt pro-tumorigenic pathways and enhance treatment responses in NHL."

Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

New Treatment Options in Chronic GVHD - Episode 5: REACH-3 Trial of Ruxolitinib in Steroid-Refractory Chronic GVHD (OncLive) - "Corey Cutler, MD, MPH, FRCPC: REACH-3 was a trial designed very similar to REACH-2; this was a randomized controlled trial where individuals were randomized to receive ruxolitinib at a dose of 10 mg twice daily or best available therapy. The list of best available therapy compounds in this study was somewhat different than the acute GVHD [graft versus host disease] trial....A significant portion, 12% to 15%, actually had grade 3 or higher anemia or thrombocytopenia. Subjects who have low counts coming into ruxolitinib therapy might require dose modifications."

Video

Subcutaneous Rituximab Prefered Over Intravenous Formulation for NHL in Clinical Practice (Journal of Clinical Pathways) - "Mitul Gandhi, MD...discusses results from a study exploring real-world data on patient and provider preferences of rituximab administration for non-Hodgkin lymphoma (NHL), showing that both parites prefer the subcutaneous administration of the drug over intravenous administration."

Video

[IgG4-related disease treatment in 2014: Update and literature review.] (PubMed) - "Immunosuppressive agents and rituximab are used as second line treatments. We review here previous studies on treatment and suggest general recommendations for the treatment and follow up of patients with IgG4-related disease."

Journal • Biosimilar • Fibrosis • Immunology • Inflammation

[Special hematological diagnostics and therapy options for ocular lymphoma taking CNS involvement into account.] (PubMed) - "Data on intraocular lymphoma are derived from small, usually retrospective and very heterogeneous studies with a relatively short follow-up. To gain more knowledge on this rare disease, inclusion of patients in the prospective registry, currently in progress in Germany, is desirable."

Journal • Biosimilar • Hematological Malignancies • Oncology